Anti-Inflammatory and DICER Activator Composition for Neuroprotection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuronal diseases such as ALS and AMD are inadequate, with a lack of effective therapies and significant inter- and intra-patient variability, and the need for safe and reliable treatments remains unmet.
Innovation Solution
A synergistic combination of an anti-inflammatory drug, such as a COX-2 inhibitor, and a DICER activator, like ciprofloxacin, is administered to enhance microRNA biogenesis and reduce neuroinflammation, targeting diseases including ALS, FTD, and AMD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for neuronal diseases are used, then treatment is provided, but effectiveness is inadequate and significant variability exists between patients
Solution Approach 1:
The patent changes the therapeutic parameters by combining two drugs with different mechanisms of action (anti-inflammatory drug targeting COX-2 and DICER activator targeting microRNA biogenesis) to create a synergistic effect that improves treatment reliability while reducing patient variability
Solution Approach 2:
The patent creates a composite therapeutic regimen combining two distinct pharmacological agents (anti-inflammatory drug and DICER activator) that work through different molecular pathways, thereby achieving more consistent and reliable treatment outcomes across diverse patient populations
2Object-affected harmful factors
If anti-inflammatory drugs are used alone, then neuroinflammation is reduced, but treatment effectiveness is limited
Solution Approach 1:
The patent merges two therapeutic approaches: anti-inflammatory drugs that reduce neuroinflammation and DICER activators that enhance microRNA biogenesis, creating a combined regimen where both mechanisms work together to achieve superior treatment effectiveness
Solution Approach 2:
The patent introduces DICER activator as an intermediary that enhances microRNA biogenesis, which in turn modulates gene expression related to neuronal protection and inflammation regulation, thereby amplifying the effect of anti-inflammatory drugs
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination shows a significant neuroprotective effect, improving motor function and reducing neurodegeneration in ALS models and retinal health in AMD, suggesting a novel therapeutic approach.
Implementation Method 1
Neuroinflammation is promoted by cyclooxygenase-2 (COX-2), and the activity of COX-2 can be inhibited by non-steroidal anti-inflammatory drugs (NSAIDs)
Implementation Method 2
enhance microRNA biogenesis and reduce neuroinflammation
Data Source
AI summary
The present invention discloses compositions, means and kits thereof for treating neuronal clinical indications in a mammalian subject. The composition comprises, inter alia, a synergistic combination of an anti-inflammatory drug and a DICER activator. The present invention further discloses methods for treating neuronal diseases including Motor neuron diseases (MNDs), ALS, FTD (Frontotemporal Dementia), macular degeneration (AMD) autism, and neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease.